FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| OMB APPROVAL | | | | | | | | |
|---|-----------|--|--|--|--|--|--|--|
| OMB Number: Estimated average burden | 3235-0287 | | | | | | | |
| hours per response: | 0.5 | | | | | | | |

| 1. Name and Address of Reporting Person [*] Carnell Clinton E. | | | | me and Ticker or Ti <mark>Jealth Co</mark> [SI | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner | | | | | | | |
|--|--|----------|----------------|---|-------------------|-------------------------------------|--|----------------------------|---------------------|----------------|--|--|--|--|
| (Last) (First) (Middle) | | (Middle) | 3. Date of Ea | arliest Transaction (| Month/Dav/Year | | X | Officer (give title below) | Other (s | specify below) | | | | |
| C/O THE BEAUTY HEALTH COMPANY | | | 07/15/202 | | | | Chief Executive Officer | | | | | | | |
| 2165 SPRING STRE | BET | | _ | | | | | | | | | | | |
| (Street) | | | 4. If Amendr | nent, Date of Origin | al Filed (Month/I | Day/Year) | 6. Individ | lual or Joint/Group Filing | (Check Applicable L | ine) | | | | |
| LONG BEACH | CA | 90806 | | | | | X | Form filed by One Re | porting Person | | | | | |
| | | | -1 | | | | | Form filed by More that | an One Reporting Pe | rson | | | | |
| (City) | (State) | (Zip) | | | | | | | | | | | | |
| | Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | |
| 1. Title of Security (Instr. 3) 2 | | | 2. Transaction | 2A. Deemed | 3. Transaction | 4. Securities Acquired (A) or Dispo | sed Of | 5. Amount of Securities | 6. Ownership | 7. Nature of | | | | |

| | | | Date (Month/Day/Year) | Execution Date, if any (Month/Day/Year) | | Code (Instr. 8) | | (D) (Instr. 3, 4 and 5) | | | Beneficially Owned Following Reported | | Form: Direct (D) or Indirect (I) (Instr. 4) | | Indirect Beneficial | | |
|--|---|--|--------------------------|---|------|---|-------------------------|--|------------|--|--|---------------------------|---|--|-----------------------------|--|--|
| | | | | | Code | v | Amount | | (A) or (D) | Price | Transaction(s) (Instr. 3 and 4) | | | | Ownership (Instr. 4) | | |
| Class A Common Stock | | | | 07/15/2021 | | | J ⁽¹⁾ | | 435,6 | 587 | Α | \$0 ⁽¹⁾ | 2,466,058 | | 8 D | | |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | Execution Date, | Code (Instr. 8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amouni Underlying Derivati (Instr. 3 and 4) | | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported | e (s ally g (| 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| | | | | Code | v | (A) | (D) | Date Exercisa | able | Expiration Date | Title | | Amount or Number of Shares | | Transacti (Instr. 4) | | |

Explanation of Responses:

1. The reported acquisition reflects earmout shares issued pursuant that certain Agreement and Plan of Merger, dated as of December 8, 2020, by and among Vesper Health Acquisition Corp, Hydrate Merger Sub I, Hydrate Merger Sub II LLC, LCP Edge Intermediate, Inc. the indirect parent of Edge Systems LLC d/b/a the HydraFacial Company and LCP Edge Holdco, LLC.

Remarks:

/s/ Paul Bokota, Attorney-in-Fact for 07/19/2021

Clinton E. Carnell ** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY CLINTON E. CARNELL

With respect to holdings of and transactions in securities issued by The Beauty Health Company (the "<u>Company</u>"), the undersigned hereby constitutes and appoints the individuals named on <u>Schedule A</u> attached hereto and as may be amended from time to time, or any of them signing singly, with full power of substitution and resubstitution, to act as the undersigned's true and lawful attorney-in-fact to:

- prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the United States Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain and/or regenerate codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934, as amended, or any rule or regulation of the SEC;
- 2. execute for and on behalf of the undersigned, Forms 3, 4, and 5 in accordance with Section 16 of the Securities Exchange Act of 1934, as amended, and the rules thereunder;
- 3. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and
- 4. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in his or her discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution and resubstitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorneys-in-fact substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted.

The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 16th day of May, 2021.

/s/ Clinton E. Carnell Clinton E. Carnell

Schedule A

Individuals Appointed as Attorney-in-Fact with Full Power of Substitution and Resubstitution

- 1. Paul Bokota
- 2. Daniel Maranon